Peanut Allergy Market Size, Share - Growth Analysis Report and Forecast Trends 2026-2030

The peanut allergy market spans therapeutic interventions, diagnostic testing, and specialized food products catering to individuals with peanut hypersensitivity. With a 2025 valuation of $0.54 billion, the market is in a relatively early but rapidly accelerating phase of commercialization. The approval of the first-ever FDA-authorized treatment for peanut allergy has been a watershed moment, transforming the market from a purely avoidance-based approach to one that includes active therapeutic options.

• •Estimated market value of $0.54 billion in 2025 with a 10.8% CAGR projected through the early 2030s
• •Oral immunotherapy (OIT) represents the most transformative product category in the current market
• •North America accounts for the largest regional share due to high prevalence and advanced healthcare infrastructure

Rising prevalence of peanut allergy, particularly among pediatric populations in developed nations, remains the primary demand driver for this market. Increased awareness and improved diagnostic methodologies have led to higher identification rates, expanding the addressable patient population. The landmark regulatory approval of peanut allergen immunotherapies has unlocked a new commercial paradigm, moving beyond strict avoidance to active treatment.

• •Growing incidence of food allergies globally, with peanut allergy affecting an estimated 1-2% of the population in many developed countries
• •Advances in diagnostic technologies, including component-resolved diagnostics, enabling more precise and earlier identification
• •Regulatory approvals and clinical pipeline depth providing a sustained stream of new product candidates through the decade

The market is broadly segmented into therapeutics (oral immunotherapy, biologics, epinephrine auto-injectors), diagnostics (skin prick tests, blood assays, component testing), and food service and consumer products. Geographically, North America leads due to high disease burden and early adoption of novel therapies, while Europe and Asia-Pacific represent growing markets driven by rising awareness and expanding healthcare access.

• •North America dominates with the highest market share, supported by advanced regulatory frameworks and strong patient advocacy
• •Europe follows as the second-largest region, with growing adoption of immunotherapy protocols across key markets
• •Asia-Pacific is the fastest-growing regional segment, driven by increasing allergy awareness and improving diagnostic infrastructure

What are the recent trends and outlook?

The market is moving toward more personalized approaches, with research focusing on biomarkers to predict treatment responders and optimize dosing regimens. Combination therapies pairing immunotherapy with biologics represent an emerging paradigm. Over the forecast period, pipeline diversification and geographic expansion are expected to sustain double-digit growth, with several late-stage candidates potentially reaching market approval.

• •Biologics such as anti-IL-4/IL-13 agents are being investigated as adjunctive therapies to enhance immunotherapy efficacy
• •Point-of-care and at-home diagnostic devices are gaining traction to support broader screening and earlier intervention
• •Pipeline diversification across OIT, epicutaneous immunotherapy, and biologic approaches is expected to intensify market competition through 2030